
Claims

1. Use of a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor in the manufacture of a medicament for treating a hematological malignancy in a subject, wherein the mutant IDH2 is to be administered to the subject with a DNA demethylating agent, the mutant IDH2 inhibitor is 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:



or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof (COMPOUND 1), and wherein the hematological malignancy is a malignancy characterized by the presence of a mutant allele of IDH2.

2. The use of claim 1, wherein the IDH2 mutation is an IDH2 R140Q or R172K mutation.


3. The use of claims 1 or 2, wherein the malignancy is acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myeloid sarcoma, multiple myeloma, lymphoma (e.g., T-cell lymphoma or B-cell lymphoma), angioimmunoblastic T-cell lymphoma (AITL) or blastic plasmacytoid dendritic cell neoplasm.

4. The use of any one of claims 1 to 3, wherein the malignancy is acute myelogenous leukemia.

5. The use of claim 4, wherein the acute myelogenous leukemia newly diagnosed.

6. Use of a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor in the manufacture of a medicament for treating a solid tumor in a subject, wherein the mutant IDH2 inhibitor is to be administered to the subject with and a DNA demethylating agent and the mutant IDH2 is

2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:



or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof thereof (COMPOUND 1), and wherein the solid tumor is characterized by the presence of a mutant allele of IDH2.

7. The use of any one of claims 1 to 6, wherein the dose of COMPOUND 1 is about 20 to 2000 mg/day.

8. The use of any one of claims 1 to 7, wherein the dose of COMPOUND 1 is about 50 to 500 mg/day.

9. The use of any one of claims 1 to 8, wherein the dose of COMPOUND 1 is about 50 mg/day.

10. The use of any one of claims 1 to 8, wherein the dose of COMPOUND 1 is about 100 mg/day.

11. The use of any one of claims 1 to 8, wherein the dose of COMPOUND 1 is about 200 mg/day.

12. The use of any one of claims 1 to 11, wherein the DNA demethylating agent is azacitidine.

13. The use of any one of claims 1 to 12, wherein the dose of azacitidine is 50 to 500 mg/m^2.

14. The use of any one of claims 1 to 13, wherein the dose of azacitidine is 50 to 200 mg/m^2.

15. The use of any one of claims 1 to 13, wherein the dose of azacitidine is about 50 mg/m^2.

16. The use of any one of claims 1 to 13, wherein the dose of azacitidine is about 60 mg/m^2.

17. The use of any one of claims 1 to 13, wherein the dose of azacitidine is about 75 mg/m^2.

18. The use of any one of claims 1 to 17, wherein COMPOUND 1 and azacitidine are to be administered concurrently.

19. The use of any one of claims 1 to 17, wherein COMPOUND 1 and azacitidine are to be administered sequentially.

20. A pharmaceutical composition, comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof, and azacitidine.

21. The use of claim 4, wherein the malignancy is acute myelogenous leukemia and wherein the composition of claim 20 is to be administered to the patient.